Skip to Content

Alnylam Pharmaceuticals Inc ALNY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

No-Moat Alnylam Reports Q1 Results Within Expectations; Maintaining Our $150 Fair Value Estimate

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

No-moat Alnylam Pharmaceuticals reported solid first-quarter results, bringing overall revenue to $178 million, driven by strong commercial execution of its RNA-based drugs. Product sales and pipeline development are tracking our expectations, and we are maintaining our $150 per share fair value estimate and no-moat rating for this developing firm.

Read Full Analysis

Company Profile

Business Description

Alnylam Pharmaceuticals Inc is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as Regeneron, Sanofi, and The Medicines Company have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Contact
675 West Kendall Street, Henri A. Termeer Square
Cambridge, MA, 02142
T +1 617 551-8200
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 1,453

Related